FOLH1 and neoplasm: FCNs have been applied with great success in a number of biomedical contexts, demonstrating the ability to segment a wide variety of clinically relevant anatomical and physiological structures such as the prostatic gross tumour volume in PSMA PET images, whole-body multiple myeloma lesions on 68Ga-Pentifaxor PET/CT scans, and glioma brain tumours on 18F-fluoro-ethyl-tyrosine (FET) PET imaging [26–28].